Progressive Supranuclear Palsy (PSP)

Progressive Supranuclear Palsy (PSP)

Study-related travel may be provided at no cost to many study participants and their study partner including flights, ground transportation, lodging, and meals for both the patient and caregiver. Travel arrangements and reimbursements may vary from study to study.

STUDY-RELATED TRAVEL WILL BE PROVIDED AT NO COST TO MANY STUDY PARTICIPANTS AND THEIR STUDY PARTNER INCLUDING FLIGHTS FROM ANYWHERE IN THE U.S., GROUND TRANSPORTATION, LODGING, AND MEALS FOR BOTH THE PATIENT AND CAREGIVER. TRAVEL ARRANGEMENTS AND REIMBURSEMENTS MAY VARY FROM STUDY TO STUDY.

Investigational Treatment for Progressive Supranuclear Palsy (PSP)

CenExel RMCR is conducting clinical studies that will provide many patients with a new investigational medication. The study seeks to determine if the investigational treatment will safely slow the progression of PSP.


Meet Dr Kumar – Watch the Video

Benefits of participating in clinical trials at no cost to you or your family:

  • Lab Work
  • Neurological Exams
  • More Access to Physicians
  • Investigational Medications (Placebo Controlled)
  • Lodging and Meals
  • Travel (Within US for caregiver & patient)

Informed Consent Is Very Important: Learn about the risks, benefits, and the clinical trials process by visiting our Clinical Trials Information Page.

A helpful resource about Progressive Supranuclear Palsy is CUREPSP

Overview

Progressive Supranuclear Palsy (PSP) is a rare neurodegenerative disease. Only five or 6 people per 100,000 will develop it. The exact cause of PSP is unknown, but the symptoms are caused by misfolding and accumulation of a naturally-occurring brain protein called tau. These accumulations become toxic and cause degeneration of brain cells.

Symptoms

PSP affects many aspects of a patient’s life. There a wide range of symptoms associated with this disease including slowness of movement, loss of balance, worsening of memory and thinking ability, personality changes, mood problems, problems with eye movements-particularly looking downwards, difficulty swallowing, slurred speech, and drooling. This disease is progressive, so symptoms emerge and worsen as the disease progresses.

Diagnosis

PSP is difficult to diagnose because the early stages often look very similar to Parkinson’s disease. One of the main diagnostic features of this disease is visual complaints. Patients with PSP have difficulty looking up or down and often complain of double vision and involuntary closing of the eyelids. Other early complaints are unexplained falls, problems with memory and thinking, and mood problems including impulsiveness, apathy and depression. When diagnosing a patient with PSP, other similar disorders, which may be treatable, should be ruled out.

Treatment

There is currently no FDA-approved treatment for PSP. Some patients may respond to anti-Parkinson medications. Levodopa may help with the slowness and stiffness, but the effect is generally much less than in Parkinson’s disease, the benefit usually diminishes significantly over time, and patients usually need a much higher dose of medication to receive benefit. Antidepressants may help mood problems in some patients. Some non-drug therapies which are helpful for some individuals include prism glasses for double vision, speech therapy, and walking aids. For patients with marked swallowing problems surgical placement of a feeding tube may help ensure nutrition and reduce the risk of pneumonia caused by food going into the lungs.

Research

There is currently extensive research ongoing to better understand the cause and progression of PSP.  It is thought that spread of misfolded tau from cell to cell plays an important role in the disease progression.  We are currently conducting a clinical trial examining whether IV infusion of an antibody against tau will reduce spread of the abnormal protein and slow the progression of the disease.  Patients who are able to walk 5 steps with minimal assistance and have had symptoms less than 5 years may be candidates for the study.

Do you or a loved one have PSP?

Please fill out the below survey to help us determine if you, or your loved one, may qualify for an investigational study aiming to potentially slow disease progression.

 

Do you or a loved one have PSP?

Please fill out the below survey to help us determine if you, or your loved one, may qualify for an investigational study aiming to potentially slow disease progression.

Has the patient been diagnosed with Progressive Supranuclear Palsy (PSP)?

Untitled(Required)

When did you first notice PSP symptoms?

Untitled(Required)

Can the patient walk 5 steps independently or with a little help (using a cane, walker, or holding onto someone with one hand)?

Untitled

Does the patient live in a nursing home?

Untitled

Your Name

First Name
Last Name

Relationship to Patient*

Untitled
If you are submitting this form on behalf of someone else, you must have that person's consent unless you have a medical power of attorney.

Phone*

Email

E-mail is generally not encrypted. If you do not wish to accept the risks associated with communicating your Personal Information by email, please provide only your phone number.

Address

Address

Agreement*

Untitled(Required)
 
We have helped tens of thousands of patients in similar studies.
Space in this study is limited. To be considered, please fill out the form or call 303-357-5455.

STUDY DETAILS

No cost studies are currently available for qualified participants.

fas|fa-file-alt|

No health insurance required

fas|fa-money-check-alt|

Compensation for time and travel TBD

fas|fa-stopwatch|

fas|fa-user|

Male / Female

fas|fa-birthday-cake|

mt|location_on|

701 E Hampden Ave, Ste 510
Englewood, CO 80113

Facility
State-of-the-Art Facilities

CenExel RMCR is Colorado's premier clinical research organization. For over 15 years, we’ve helped improve the quality of life for everyone by researching new medications and treatments. Our state-of-the-art facility is held to the highest standards of cleanliness and quality.

Board-Certified Physician

Your safety is our greatest concern. Every study at CenExel RMCR is overseen by expert medical staff and one of the most well-respected, board-certified physicians in the clinical research industry with 25+ years of experience.

FDA-Approved Procedures

Rest assured, you are not signing up for treatment with “experimental” methods. RMCR only uses FDA approved methods as if you were at any other hospital or clinic. Our research is focused on the medication associated with those methods.

Frequently asked questions

What is a CenExel Center of Excellence?

CenExel Centers of Excellence provide unparalleled medical and scientific support in the design and execution of clinical trials. Their attention to detail assures quality, reliable results and has helped CenExel to consistently achieve and exceed patient recruitment goals. They have conducted thousands of studies, the variety and complexity of which have resulted in a great depth of experience and insight for the principal investigators and research staff in each facility. CenExel Centers of Excellence deliver the engagement, expertise, and results to ensure that clients achieve their clinical research goals.

How do clinical trials work?

The study procedures and process will vary depending on the type of clinical trial you participate in. Before you begin a study, the process and all procedures for that study will be explained to you. Throughout the study, the Study Coordinator and the Principal Investigator will assist you and can answer any questions you have. They will check your health at the beginning of the trial, give you specific instructions for participating in the trial, monitor you carefully during the trial, and stay in touch with you after the study.

Some clinical trials involve more tests and doctor visits than you would normally have for your illness or condition. Your participation will be most successful if you carefully follow all instructions you are given and stay in contact with the research staff.

How safe are clinical studies?

There are many safeguards in place that all companies must follow when conducting clinical trials.

The Food and Drug Administration (FDA) is the regulatory agency that oversees all clinical research conducted in the United States. It is their responsible to protect the rights and as much as possible, the welfare of subjects participating in clinical trials. They ensure that data collected from clinical trials is of the highest quality and they are the agency that determines whether a new treatment should be sold in the US. Several organizations and individuals are governed by FDA regulations including clinical investigators, sponsors (the companies developing the treatments), Contract Research Organizations (companies that help conduct the studies), and Institutional Review Boards (groups that are responsible for ensuring the safety and welfare of study participants).

Good Clinical Practice (GCP) guidelines are another safeguard implemented to protect the safety of subjects. These guidelines encompass federal regulations and industry-accepted standards that govern clinical trials on humans. These regulations and standards apply to the conduct of the studies, record keeping, informed consent of subjects, collection of scientific data, and submission of information needed for the FDA to determine whether a new treatment should or should not be sold in the US. All companies must follow these guidelines when conducting clinical research.

An Institutional Review Board (IRB) is a committee that is formally tasked by an institution to review, approve, and monitor research involving human subjects. IRBs ensure that the risks to subjects are minimized; that subjects are adequately informed about the trial and the implications it will have on their treatment; that study protocols are modified, when necessary, to ensure safety; that risks are reasonable in relation to the anticipated benefits and the importance of the knowledge to be gained; that subject selection is equitable and that no classes of patients are discriminated against; that informed consent is obtained; that there is a provision for safety monitoring in the research plan; and that here are adequate provisions for the privacy and confidentiality for subjects and the data collected.

Translate »